• Type:

iPS-derived immune cells for oncology: promises and challenges

Play

Justin Eyquem is quite a unique witness of the emergence of CAR-T cell therapies. He did his PhD in partnership with CAR-T company Cellectis. In 2014, he joined the lab of Michel Sadelain at the MSKCC, who co-founded Juno Therapeutics and is now involved with leading CAR-T cell companies such as Fate Therapeutics and Atara Biotherapeutics. Justin eventually established his own lab at USCF and co-founded Mnemo Therapeutics with Michel Sadelain in 2018. In this episode, I asked him about his feelings on the pros and cons of iPS cells for immuno-oncology applications.

Reviews for iPS-derived immune cells for oncology: promises and challenges

There are currently no reviews for iPS-derived immune cells for oncology: promises and challenges
Scroll to top